Poultry-derived PCV2 gene and application thereof
By providing avian source PCV2 gene and its applications, including ELISA detection plates, inactivated vaccines and efficient isolation methods, the problems of PCV2 isolation difficulty and lack of vaccines in the prior art are solved, efficient isolation and stable passage are achieved, and poultry is provided. significant protection and accurate detection.
Patent Information
- Application Number
- CN202411172833.6
- Authority / Receiving Office
- CN · China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- Filing Date
- 2024-08-23
- Publication Date
- 2024-11-15
- Estimated Expiration
- 2044-08-23
AI Technical Summary
The prior art is difficult to efficiently isolate and subcategorize the pig circovirus (PCV2), and there is a lack of effective vaccines and diagnostic tools, which affects the rapid isolation of viral infectious diseases and the prevention and control of epidemics.
Provide avian source PCV2 genes and their applications, including the preparation of ELISA detection plates, inactivated vaccines, subunit vaccines, as well as efficient isolation methods and MDCC-MSB1 cell lines for the isolation and culture of PCV2.
The efficient isolation and stable passage of PCV2 virus strains has been achieved, providing significant protection against poultry and can accurately detect PCV2, with high specificity and repeatability.
Smart Images

Figure CN118956905A_ABST
Abstract
Description
Technical Field
[0001] The invention belongs to the technical field of animal virology and immunology, and in particular relates to an avian PCV2 gene and application thereof. Background Art
[0002] Porcine circovirus (PCV) is a small non-enveloped virus with a single-stranded circular DNA genome. It belongs to the genus Circovirus of the family Circoviridae. To date, at least four porcine circoviruses (PCVs) have been discovered, including PCV1 to PCV4. PCV2 was first discovered in Canada in the early 1990s. The disease caused by the virus was subsequently named porcine circovirus-associated disease (PCVAD) in North America. The characteristics of PCVAD mainly include post-weaning multisystemic wasting syndrome (PMWS), porcine dermatitis and nephropathy syndrome (PDNS), reproductive disorders, enteritis, and respiratory diseases. In addition, the immune system of pigs subclinically infected with PCV2 will be suppressed, which is conducive to the infection of other viruses, and mixed infection will show more severe clinical symptoms. (Afghah et al., 2017; Opriessnig et al., 2007; Saha et al., 2011). PCV2 is currently divided into six major genotypes (PCV2a, PCV2b, PCV2c, PCV2d, PCV2e and PCV2f), of which PCV2b and PCV2d are the main strains in China. The complete genome of PCV2 is 1766 or 1768 bp, encoding at least 11 predicted open reading frames (ORFs).
[0003] So far, many hosts have been found to be infected with PCV2, such as pigs, wild boars, mice, calves, minks, dogs, foxes and goats, and pigs are its natural hosts. There are no reports that PCV2 can infect poultry. For viral infectious diseases, rapid and effective isolation of pathogens is the key to diagnosis and epidemic prevention and control. Cells that can continuously proliferate the virus are one of the most important tools for viral diagnosis and subsequent research. Previously, Zhu et al. (Zhu et al., 2007) reported that the PK-15 cell population was heterogeneous in terms of permissibility to PCV2 infection, with only about 20% of the cell population susceptible to infection (Tischer et al., 1987), and the virus titer never exceeded 10 5 TCID50 titer (Meerts et al., 2005). At present, it is still difficult to efficiently separate and propagate PCV2 in vitro, and there are problems such as high separation difficulty, low separation rate, and unstable separation rate. At the same time, there is no mature PCV2 vaccine yet. Summary of the invention
[0004] In view of this, the object of the present invention is to provide an avian PCV2 (aPCV2) gene and its use in the preparation of PCV2 vaccine.
[0005] Another object of the present invention is to provide an ELISA test plate for detecting PCV2, an inactivated vaccine and a subunit vaccine.
[0006] Another object of the present invention is to provide a method for efficiently isolating avian PCV2 or swine PCV2 and the use of MDCC-MSB1 cell line in isolating and culturing PCV2.
[0007] In order to achieve the above-mentioned object of the invention, the present invention provides the following technical solutions:
[0008] The present invention provides an aPCV2 gene, wherein the nucleotide sequence of the aPCV2 gene comprises any one of the following: (1) SEQ ID NO.1, (2) SEQ ID NO.2, (3) a sequence having a homology of more than 90% with SEQ ID NO.1, (4) a sequence having a homology of more than 90% with SEQ ID NO.2.
[0009] The present invention also provides the use of the aPCV2 gene in preparing PCV2 vaccine.
[0010] The present invention also provides an expression vector, which contains the Cap gene or the Rep gene in the aPCV2 gene, wherein the nucleotide sequence of the Cap gene includes SEQ ID NO.3 or SEQ ID NO.4, and the nucleotide sequence of the Rep gene includes SEQ ID NO.5 or SEQ ID NO.6.
[0011] The present invention also provides a host cell, wherein the host cell contains the above expression vector.
[0012] The present invention also provides a recombinant protein, which is obtained by inducing the above host cell to express and purify.
[0013] The present invention also provides the use of the above expression vector, the above host cell or the above recombinant protein in preparing a product for detecting PCV2 or in preparing a PCV2 vaccine.
[0014] The present invention also provides an ELISA detection plate for detecting PCV2, wherein the ELISA detection plate is coated with the above-mentioned recombinant protein, and the coating concentration of the recombinant protein is 1.0 μg / ml-2.0 μg / ml.
[0015] The present invention also provides an inactivated vaccine, comprising a virus strain containing the aPCV2 gene.
[0016] The present invention also provides a subunit vaccine, comprising the above-mentioned recombinant protein and an adjuvant.
[0017] The present invention also provides a method for efficiently isolating PCV2, comprising the following steps: injecting PCV2 virus liquid into the allantoic cavity of 8-11 day old avian embryos, collecting the allantoic fluid after incubation to obtain PCV2 virus, wherein the PCV2 virus liquid comprises avian PCV2 virus liquid or swine PCV2 virus liquid, and the avian PCV2 virus liquid is a virus liquid of a virus strain containing the above-mentioned aPCV2 gene.
[0018] The present invention also provides the use of the MDCC-MSB1 cell line in isolating and culturing porcine PCV2 or avian PCV2, wherein the avian PCV2 is a virus strain containing the aPCV2 gene.
[0019] Beneficial effects of the present invention:
[0020] The present invention provides an aPCV2 gene for the first time, and the virus strain containing the aPCV2 gene has a high virus titer and can be stably propagated multiple times. The inactivated vaccine prepared using the virus strain containing the aPCV2 gene of the present invention has a significant protective effect on poultry such as chickens, ducks, and geese. The subunit vaccine prepared using the Cap gene or the Rep gene in the aPCV2 gene of the present invention also has a significant protective effect on poultry such as chickens, ducks, and geese. The ELISA test plate prepared using the Rep gene or the Cap gene in the aPCV2 gene of the present invention can accurately detect PCV2 and has high specificity and repeatability.
[0021] The method for isolating PCV2 provided by the present invention can efficiently separate porcine PCV2 and aPCV2 in vitro, and has the advantages of low separation difficulty, high separation rate and stable separation rate. At the same time, the present invention proposes for the first time that the MDCC-MSB1 cell line can be used for the separation and cultivation of PCV2, and has the advantage of being able to be stably propagated. BRIEF DESCRIPTION OF THE DRAWINGS
[0022] Figure 1 This is the agarose gel electrophoresis diagram of PCV2 Cap detection of poultry clinical samples. M in the figure represents 2000bp DNA Marker, 1 and 2 represent chicken kidney tissue samples, 3 and 4 represent chicken serum samples, 5 and 6 represent duck kidney tissue samples, 7 and 8 represent chicken serum samples, "─" represents negative control, and "+" represents PCV2 positive control;
[0023] Figure 2 This is a genetic evolutionary analysis diagram of the entire genome of avian PCV2 and circoviruses of other species;
[0024] Figure 3This is the complete genome of aPCV2 isolate aPCV2-duck-GDYF1, in which the yellow color represents the ORF1 gene sequence and the green color represents the ORF2 gene sequence;
[0025] Figure 4 This is the complete genome of aPCV2 isolate aPCV2-chicken-GDQY2, in which the yellow represents the ORF1 gene sequence and the green represents the ORF2 gene sequence;
[0026] Figure 5 It is a comparison diagram of the amino acid sequences of ORF1 and ORF2 of the five isolated aPCV2 strains, where A is the Rep gene and B is the Cap gene;
[0027] Figure 6 It is a homology analysis diagram of the 5 isolated aPCV2 isolates;
[0028] Figure 7 Agarose gel electrophoresis of aPCV2 Cap detection of aPCV2-duck-GDYF1 strain F2-F15 isolated from MDCC-MSB1 cells;
[0029] Figure 8 Agarose gel electrophoresis diagram of aPCV2 Cap detection of aPCV2-chicken-GDQY2 strain F2-F15 isolated from MDCC-MSB1 cells;
[0030] Fig. 9 The results of transmission electron microscopy, where Figure A shows the results of aPCV2-duck-GDYF1 and Figure B shows the results of aPCV2-chicken-GDQY2;
[0031] Fig.10 The antibody levels after immunization with inactivated aPCV2, of which the left picture shows the results of aPCV2-chicken-GDQY2 inactivated vaccine, and the right picture shows the results of aPCV2-duck-GDYF1 inactivated vaccine;
[0032] Fig.11 The aPCV2 virus copy numbers in different tissues of chickens immunized with inactivated vaccines are shown in the left figure. The results of aPCV2-chicken-GDQY2 inactivated vaccine (denoted as GDQY2 inactivated vaccine) and the results of aPCV2-duck-GDYF1 inactivated vaccine (denoted as GDYF1 inactivated vaccine) are shown in the right figure. *** indicates extremely significant differences.
[0033] Fig.12 This is the aPCV2-duck-GDYF1 Cap PCR amplification diagram, where the left band is the 2000 bp DNA Marker;
[0034] Fig.13 This is the aPCV2-duck-GDYF1 Rep PCR amplification diagram, where the left band is the 2000 bp DNA Marker;
[0035] Fig.14 The purification results of YF-aPCV2 Cap recombinant protein, where M is 8-180 protein marker, 1 is direct current sample, 2 is 20mmol imidazole elution, 3 is 50mmol imidazole elution, 4 is 100mmol imidazole elution, 5 is 200mmol imidazole elution, 6 is 300mmol imidazole elution, and 7 is 500mmol imidazole elution.
[0036] Fig.15 The purification results of YF-aPCV2 Rep recombinant protein, where M is 8-180 protein marker, 1 is direct current sample, 2 is 20mmol imidazole elution, 3 is 50mmol imidazole elution, 4 is 100mmol imidazole elution, 5 is 200mmol imidazole elution, 6 is 300mmol imidazole elution, and 7 is 500mmol imidazole elution;
[0037] Fig.16 The Western-blot identification results of YF-aPCV2 Cap recombinant protein, where M is 8-180 protein marker, 1 is 20mmol imidazole elution, 2 is 50mmol imidazole elution, 3 is 100mmol imidazole elution, 4 is 200mmol imidazole elution, 5 is 300mmol imidazole elution, and 6 is 500mmol imidazole elution;
[0038] Fig.17 The Western-blot identification results of YF-aPCV2 Rep recombinant protein, where M is 8-180 protein marker, 1 is 20mmol imidazole elution, 2 is 50mmol imidazole elution, 3 is 100mmol imidazole elution, 4 is 200mmol imidazole elution, 5 is 300mmol imidazole elution, and 6 is 500mmol imidazole elution;
[0039] Fig.18 is the antibody level after immunization with aPCV2 Cap protein;
[0040] Fig.19 It is the antibody level after immunization with aPCV2 Rep protein;
[0041] Fig. 20 The results of PCV2 virus copy numbers in different tissues after immunization with aPCV2 Cap, **** indicates extremely significant differences;
[0042] Fig.21The results of PCV2 virus copy numbers in different tissues after immunization with aPCV2 Rep, **** indicates extremely significant differences;
[0043] Fig. 22 This is a WB verification of the effect of aPCV2 infection on MDCC-MSB1 cells;
[0044] Fig.23 This is an IFA validation diagram of the effect of aPCV2 infection on MDCC-MSB1 cells;
[0045] Fig.24 is the number of PCV2 virus copies in the allantoic fluid, **** indicates extremely significant difference. DETAILED DESCRIPTION
[0046] The present invention provides an avian PCV2 (aPCV2) gene, wherein the nucleotide sequence of the aPCV2 gene comprises any one of the following: (1) SEQ ID NO.1, (2) SEQ ID NO.2, (3) a sequence having a homology of more than 90% with SEQ ID NO.1, and (4) a sequence having a homology of more than 90% with SEQ ID NO.2.
[0047] The present invention proposes for the first time that PCV2 can infect poultry, and separates poultry-derived aPCV2 strains from poultry and identifies them as PCV2b strains. The inactivated vaccine prepared using the virus strain containing the aPCV2 gene of the present invention and the subunit vaccine prepared using the Cap gene or the Rep gene in the aPCV2 gene of the present invention both have protective effects on poultry such as chickens, ducks, and geese. The ELISA test plate prepared using the Cap and Rep genes in the aPCV2 gene of the present invention can accurately detect the serum antibody level of poultry and has the characteristics of high specificity and repeatability.
[0048] In the present invention, the poultry source includes chicken source and duck source. The present invention isolated and obtained 5 strains from kidney tissue and serum samples of chicken and duck sources, and the similarity of their nucleotide sequences was high, among which the nucleotide sequence of aPCV2-duck-GDYF1 strain was shown in SEQ ID NO.1, and the nucleotide sequence of aPCV2-chicken-GDQY2 strain was shown in SEQ ID NO.2. The nucleotide sequences of the remaining 3 strains were highly homologous to SEQ ID NO.1 or SEQ ID NO.2, respectively.
[0049] The present invention also provides the use of the aPCV2 gene in the preparation of PCV2 vaccines. In the present invention, the types of vaccines include inactivated vaccines and subunit vaccines.
[0050] The present invention also provides an expression vector, which contains the Cap gene or the Rep gene in the aPCV2 gene, wherein the nucleotide sequence of the Cap gene includes SEQ ID NO.3 or SEQ ID NO.4, and the nucleotide sequence of the Rep gene includes SEQ ID NO.5 or SEQ ID NO.6.
[0051] In the present invention, the nucleotide sequence of the Cap gene in the aPCV2-duck-GDYF1 strain whose nucleotide sequence is shown in SEQ ID NO.1 is shown in SEQ ID NO.3, the nucleotide sequence of the Rep gene in the aPCV2-duck-GDYF1 strain whose nucleotide sequence is shown in SEQ ID NO.1 is shown in SEQ ID NO.5, the nucleotide sequence of the Cap gene in the aPCV2-chicken-GDQY2 strain whose nucleotide sequence is shown in SEQ ID NO.2 is shown in SEQ ID NO.4, and the nucleotide sequence of the Rep gene in the aPCV2-chicken-GDQY2 strain whose nucleotide sequence is shown in SEQ ID NO.2 is shown in SEQ ID NO.6. In the present invention, the vector preferably includes the prokaryotic expression vector pET-28a.
[0052] The present invention also provides a host cell, the host cell containing the above expression vector. In the present invention, the host cell preferably includes Escherichia coli DH5α and Escherichia coli BL21 (DE3).
[0053] The present invention also provides a recombinant protein, which is obtained by inducing the above host cell to express and purify.
[0054] The present invention also provides the use of the above expression vector, the above host cell or the above recombinant protein in preparing a product for detecting PCV2 or in preparing a PCV2 vaccine. In the present invention, the product for detecting PCV2 preferably comprises an ELISA kit.
[0055] The present invention also provides an ELISA test plate for detecting PCV2, wherein the ELISA test plate is coated with the above-mentioned recombinant protein, and the coating concentration of the recombinant protein is 1μg / ml-2.0μg / ml. In the present invention, the preparation method of the ELISA test plate preferably comprises the following steps: diluting the PCV2 cap protein or PCV2 Rep protein to a concentration of 1μg / ml-2.0μg / ml with phosphate buffer, then adding 100μL / well to the ELISA plate, incubating, washing, patting dry, blocking, washing, and drying to obtain.
[0056] The present invention also provides an inactivated vaccine, comprising a virus strain containing the aPCV2 gene. The inactivated vaccine is obtained by inactivating the virus strain containing the aPCV2 gene. In the present invention, the inactivation is preferably performed using binary ethyleneimine (BEI).
[0057] The present invention also provides a subunit vaccine, comprising the above recombinant protein and an adjuvant. In the present invention, the adjuvant preferably comprises Freund's adjuvant, and in the subunit vaccine of the present invention, the concentration of the recombinant protein is preferably 0.3 mg / mL-0.35 mg / mL.
[0058] The present invention also provides a method for efficiently isolating PCV2, comprising the following steps: injecting PCV2 virus liquid into the allantoic cavity of 8-11 day old avian embryos, collecting the allantoic fluid after incubation to obtain PCV2 virus, wherein the PCV2 virus liquid comprises avian aPCV2 virus liquid or swine PCV2 virus liquid, and the avian aPCV2 virus liquid is a virus liquid of a virus strain containing the above-mentioned aPCV2 gene.
[0059] In the present invention, the avian embryo preferably includes chicken embryo or duck embryo, the incubation temperature is preferably 37° C., and the incubation time is preferably 72 h.
[0060] The present invention also provides the use of the MDCC-MSB1 cell line in isolating and culturing porcine PCV2 or avian aPCV2, wherein the avian aPCV2 is a virus strain containing the aPCV2 gene.
[0061] The technical solutions provided by the present invention are described in detail below in conjunction with the embodiments, but they should not be construed as limiting the protection scope of the present invention.
[0062] In the following embodiments, unless otherwise specified, all of them are conventional methods.
[0063] Unless otherwise specified, the materials and reagents used in the following examples can be obtained from commercial sources.
[0064] Example 1
[0065] Isolation and identification of porcine circovirus type 2 (aPCV2) from avian origin
[0066] 1.1a PCV2 detection
[0067] PCR amplification detection
[0068] Total viral nucleic acid was extracted from the chicken and duck kidney tissues and serum samples positive for porcine circovirus type 2. The specific operation of viral nucleic acid extraction was strictly carried out in accordance with the instructions of the viral total DNA / RNA extraction kit of Meiji Biotechnology Co., Ltd. The extracted total nucleic acid was amplified by PCR using the primers shown in Table 1. The reaction system of PCR amplification is shown in Table 2, and the reaction procedure of PCR amplification is shown in Table 3.
[0069] Table 1 Primer sequences
[0070] Primer name Primer sequence (5'-3') GenBank sequence number aPCV2CapF ATGGTTTTATTATTCATTAAGGGTTAAGTGGGGG(SEQ ID NO.7) MG732815.1 aPCV2CapR TCAGATATGACGTATCCAAGGAGG(SEQ ID NO.8) MG732815.1 aPCV2RepF AGCAACATGCCCAGCAAAAAGAAT(SEQ ID NO.9) MG732815.1 aPCV2RepR AAAAAGACTCAGTAATTTATTTCATATGGAAATTCAGGGCATG(SEQ ID NO.10) MG732815.1 aPCV2F TCGTAATGGTTTTTTATTCATTAAGGGTTAAGTGGGG(SEQ ID NO.11) MG732815.1 aPCV2R AGTGATAAAAAAGACTCAGTAATTTATTTCATATGG(SEQ ID NO.12) MG732815.1 QV2Q GTAGAAGCTCTTTATCGGAGG(SEQ ID NO.13) MG732815.1 aPCV2Q1R AACTACTCCTCCCGCCATACCATA(SEQ ID NO.14) MG732815.1 QV2 TTTGACTGTGGTTCGCTTGATAGTATATCC(SEQ ID NO.15) MG732815.1 QV2Q AGGAGCTCCACATTCCATCAGTAAGTT(SEQ ID NO.16) MG732815.1 Q3F ACACCCCACCTCCAGGGGTTTCGCTAATTTT(SEQ ID NO.17) MG732815.1 aPCV2Q3R AACAGTATATACGACCAGGAATACAATATC(SEQ ID NO.18) MG732815.1 Q4F ATCTAGGACAGGTTTGGGGGTAAAAGTA(SEQ ID NO.19) MG732815.1 Q4R AGCCATCTTGGCCAGATCCTC(SEQ ID NO.20) MG732815.1
[0071] Table 2 PCR amplification reaction system
[0072] Components Volume (μL) 2×TaqMasterMix 12.5 Forwardprimer 1 Rorward Primer 1 Total nucleic acid 2 <![CDATA[ddH2O]]> Make up 20
[0073] Table 3 PCR amplification reaction program
[0074] step temperature time Number of cycles Pre-denaturation 95℃ 5min 1 transsexual 95℃ 30s 35 annealing 58℃ 30s 35 extend 72℃ 60s 35 Final extension 72℃ 5min 1 save 4℃ ∞ 1
[0075] After PCR, the PCR amplification products were detected by 1% agarose gel electrophoresis. DEPC water was used as a negative control and pCDNA3.1-PCV2 plasmid was used as a PCV2 positive control. Figure 1 As shown in the figure, specific positive bands were detected in all samples, indicating that aPCV2 virus exists in the poultry tissue.
[0076] The whole genome of aPCV2 was amplified according to the designed primers, and a total of 5 strains were obtained from the collected diseased materials. In order to determine the genetic distance between the PCV2 detected in chicken and duck sources and circoviruses of other species, the genetic evolutionary tree analysis of the 5 isolated PCV2 strains was carried out. The results showed that the genetic distance between the chicken and duck PCV2 and the pig PCV2 was close, and they were in the same branch and in the PCV2b branch, such as Figure 2 The sequence of the aPCV2-duck-GDYF1 mutant is shown in Figure 3 The complete genome sequence of aPCV2-chicken-GDQY2 strain is shown in Figure 4 Then, amino acid comparisons were performed on the avian PCV2 ORF1, ORF2 and swine PCV2 ORF1, ORF2 genes in MegAlign. The amino acid comparison results are shown in Figure 5 Then, the base homology analysis of poultry PCV2 and pig PCV2 was performed in MegAlign. The results are shown in Figure 6 , and found that the homology was above 94%, and the highest homology was with the PCV2b branch strain.
[0077] 1.2 Cultivation of MDCC-MSB1 cells and isolation of aPCV2
[0078] (1) Cell recovery: Adjust the thermostatic water bath to 37°C in advance. When the water temperature reaches 37°C, take out the frozen MDCC-MSB1 cells from the liquid nitrogen tank and shake them quickly in the 37°C water bath to thaw. Then disinfect the outside of the cryopreservation tube with 75% medical alcohol, centrifuge at 800 r / min for 5 min, discard the cryopreservation solution, add 1 mL of warmed 1640 cell culture medium, mix gently by pipetting, and then transfer to a T25 cell culture flask. After culturing in a constant temperature incubator at 39°C and 5% CO2 for 8 h, transfer to a conical cell culture flask and perform suspension culture at 39°C, 5% CO2, and 100 r / min.
[0079] (2) Isolation of aPCV2-duck-GDYF1 and aPCV2-chicken-GDQY2 strains: The PCR-positive chicken and duck samples were chopped up with sterilized scissors, then added with autoclaved and cooled PBS, ground on ice, and then centrifuged at 10,000 r / min for 5 min. The supernatant was transferred to another 5 mL centrifuge tube, and then filtered with a 0.45 μm filter in a sterile clean bench, and then filtered with a 0.22 μm filter, and then stored in a -80°C refrigerator for later use. When the number of MDCC-MSB1 cells grew to 2×10 6 After that, the cells were collected by centrifugation at 800 r / min for 5 min, and then the tissue filtrate was diluted with sterile 1640 cell culture medium at a volume ratio of 10%, and then added to the cell pellet, the cells were gently resuspended, and incubated in a constant temperature incubator at 39°C, 5% CO2 for 2 h. The cells were collected by centrifugation at 800 r / min for 5 min, 5 ml of fresh 1640 culture medium was added, and then 300 mM D-glucosamine was added, and the culture was continued for 72 hours, and then stored at -80°C. This operation was blindly propagated to the 15th generation.
[0080] (3) PCR amplification and identification
[0081] The aPCV2-duck-GDYF1 and aPCV2-chicken-GDQY2 virus solutions obtained in step (2) were further subcultured on MDCC-MSB1 cells for 15 generations, and 200 μL of the cell cultures of the 2nd, 5th, 10th, and 15th generations were selected during this process. The total viral nucleic acid was extracted from the samples, and the extracted total nucleic acid was amplified by PCR (the total nucleic acid extraction and reaction system and procedure were the same as those in step 1.1). The Cap gene was amplified using primers aPCV2Cap F1: ATTATTCATTAAGGGTTAAGTGGGGGGTCTTT (SEQ ID NO. 21) and aPCV2 Cap R1: TCAGATATGACGTATCCAAGGAGGCGT (SEQ ID NO. 22). The results are as follows: Figure 7 , Figure 8 As shown, specific positive bands were detected in cell culture samples of different generations of the isolated strain of the present invention from the 2nd generation to the 15th generation. This shows that the isolated strains aPCV2-duck-GDYF1 and aPCV2-chicken-GDQY2 of the present invention can be continuously passaged in MDCC-MSB1. The PCR amplification products were sequenced, and the sequencing results showed that the Cap gene sequence of the aPCV2-duck-GDYF1 isolated strain is shown in SEQ ID NO.3, and the Cap gene sequence of the aPCV2-chicken-GDQY2 isolated strain is shown in SEQ ID NO.4
[0082] (4) Electron microscopy observation
[0083] Take aPCV2-duck-GDYF1 and aPCV2-chicken-GDQY2 virus liquid, centrifuge at 10000r / min for 30 minutes, take the supernatant and centrifuge at 40000r / min for 5 hours, discard the supernatant, dissolve the precipitate with 0.5mL deionized water, and then send the sample to the testing center of South China Agricultural University for sample preparation, and then observe it under transmission electron microscopy, such as Fig. 9 As shown, the results show that there are a large number of virus particles in the sample, with a diameter of about 16-18nm and a uniform particle size.
[0084] (5) Virus titer determination
[0085] Take the 5th, 10th and 15th generation virus liquid of aPCV2-duck-GDYF1 and aPCV2-chicken-GDQY2 and dilute them 10 times to 10 -1 ~10 -8, inoculated into PK-15 monolayer cells cultured in 96-well plates, inoculated into 8 wells for each dilution, added 0.1 mL of virus dilution solution to each well, cultured in a 37°C, 5% CO2 incubator, performed IFA detection after 96 hours, and calculated the virus TCID according to the Reed-Muench method 50 The test results showed that the virus titers of the 5th, 10th and 15th generations of aPCV2-duck-GDYF1 were 10 4.5 TCID 50 / mL, 10 7 TCID 50 / mL, 10 7 TCID 50 / mL, the virus titer of aPCV2-chicken-GDQY2 at the 5th, 10th, and 15th passages was 10 5 TCID 50 / mL, 10 7.5 TCID 50 / mL, 10 7 TCID 50 / mL.
[0086] Example 2
[0087] Preparation of inactivated vaccines of porcine circovirus type 2 aPCV2-duck-GDYF1 and aPCV2-chicken-GDQY2 strains from avian origin
[0088] 2.1a Preparation of PCV2 seed virus: The preparation method is the same as 1.2 in Example 1.
[0089] 2.2a Preparation of PCV2 inactivated vaccine virus liquid:
[0090] (1) Cell recovery: Adjust the constant temperature water bath to 37°C in advance. When the water temperature reaches 37°C, take out the desired frozen MDCC-MSB1 cells from the liquid nitrogen tank and shake them quickly in a 37°C water bath to thaw. Then disinfect the outside of the cryopreservation tube with 75% medical alcohol, centrifuge at 800 r / min for 5 min, discard the cryopreservation solution, add 1 mL of warmed 1640 cell culture medium, mix gently by pipetting, and then transfer to a T25 cell culture flask. After culturing in a constant temperature incubator at 39°C and 5% CO2 for 8 h, transfer to a conical cell culture flask and culture at 39°C, 5% CO2, and 100 r / min.
[0091] (2) Cell expansion culture
[0092] The cells were cultured for 72 hours and the cell density was 5.0 × 10 6 / ml, using 1640 medium to make a density of 1×10 6The cell suspension of 100 ml / ml is divided into cell shaking bottles and cultured in a 39°C, 5% CO2 incubator. After 72 hours, it can be passaged at a ratio of 1:3-1:4 (equivalent to 100 ml of cell suspension can be expanded to 400-500 ml system culture).
[0093] (3) Virus inoculation
[0094] When the cell density reaches 5.0×10 6 When the cell density is 1 cell / ml, centrifuge at 800r / min for 5 minutes, then add fresh culture medium to resuspend the cells, pipette the cell suspension into a cell shake flask, add four times (40ml) of culture medium, and inoculate 10% of the virus stock solution by the volume of the culture medium. Culture for 72 hours to obtain the virus.
[0095] 2.3a Purity test of PCV2 inactivated vaccine virus liquid
[0096] The test was carried out according to the appendix of the current "Chinese Veterinary Pharmacopoeia", and the results showed that the basic toxin species was not contaminated with bacteria, mycoplasma and exogenous viruses.
[0097] 2.4a Inactivation of PCV2 inactivated vaccine virus liquid
[0098] (1) Preparation of diethyleneimine (BEI)
[0099] Mix equal volumes of 2 mol / L 2-bromoethylamine hydrobromide (BEA) and 2 mol / L NaOH solution, place in a 37°C water bath, shake once every 10 to 15 minutes, and cyclize to produce diethylenimine (BEI) after 60 minutes, with a final concentration of 1 mol / L;
[0100] (2) Virus inactivation
[0101] Take the poultry porcine circovirus type 2 antigen liquid after cell disruption, add the BEI prepared in step (1) to its concentration of 2 mmol / L, then add formaldehyde with a volume ratio of 0.8‰, place it in a 37°C constant temperature shaker at 120 rpm / min for inactivation for 24 hours, and finally add sodium thiosulfate with a final concentration of 2 mmol / L to terminate the inactivation.
[0102] 2.5 Vaccine preparation
[0103] (1) Preparation of oil phase: Take white oil for injection, add SPAN-80 and mix, then add aluminum stearate and heat while stirring until transparent.
[0104] (2) Preparation of aqueous phase: Take Tween-80, put it into a bottle with a glass ball for sterilization, add inactivated porcine circovirus type 2 strain antigen solution after cooling, and shake thoroughly to dissolve the Tween-80 completely.
[0105] (3) Vaccine preparation: Emulsify the oil phase and place it in a high-speed shearing machine, stir it at 300 rpm for 10 minutes, slowly add the water phase, and emulsify it at 3000 rpm for 30 minutes. Quantitatively divide it into packages and seal it at 4°C.
[0106] According to the above process, aPCV2-chicken-GDQY2 inactivated vaccine and aPCV2-duck-GDYF1 inactivated vaccine were prepared respectively for the following immune protection effect detection.
[0107] 2.6 Immune protection effect detection
[0108] 20 15-day-old SPF chickens and 20 15-day-old ducklings were purchased, and the 20 SPF chickens were divided into two groups (PBS placebo group and aPCV2-chicken-GDQY2 inactivated vaccine group), and the 20 ducklings were divided into two groups (PBS placebo group and aPCV2-duck-GDYF1 inactivated vaccine group). The first immunization was recorded as the first day, and the second immunization was performed 14 days later. The virus was challenged on the 35th day. Each of the control group received 400 μl PBS, and each of the experimental group received 400 μl virus liquid. The serum collected on days 0-35 was tested for antibodies. The results are as follows: Fig.10 As shown, serum was collected on days 42 and 49 for preliminary viral copy number testing to see whether aPCV2 replicated in vivo. The experimental animals were killed on day 49 and samples were collected for testing. The results are shown in Fig.11 As shown, it is shown that the inactivated vaccine prepared by the present invention has a protective effect on poultry.
[0109] Example 3
[0110] (1) Construction of recombinant expression plasmids pET-28a-YF-aPCV2 cap and pET-28a-YF-aPCV2 Rep
[0111] Using the nucleic acid of porcine circovirus type 2 aPCV2-duck-GDYF1 strain as a template, PCR amplified aPCV2 Cap and Rep gene fragments, the amplification primers are shown in Table 4, the amplification reaction system and the reaction procedure are shown in Table 2 and Table 3 respectively; then Cap was double-digested with ScaI and XhoI, and Rep was double-digested with XhoI and BmtI, and then connected with the prokaryotic expression vector pET-28a treated with the same enzymes to construct prokaryotic expression plasmids pET-28a-YF-aPCV2 Cap and pET-28a-YF-aPCV2 Rep, and the recombinant expression plasmids were transformed into Escherichia coli DH5α, and multiple single colonies were randomly picked and inoculated in 2mL LB / Ampr culture medium, and shaken at 37°C for 8h. Then PCR identification and enzyme digestion identification were performed, and the results were as follows Fig.12 and Fig.13As shown, the PCR product was sent to the company for sequencing confirmation. Then the accurate bacterial solution was shaken (200 mL) and then the plasmid was extracted.
[0112] The construction of recombinant expression plasmids pET-28a-QY-aPCV2 cap and pET-28a-QY-aPCV2 Rep is the same.
[0113] Table 4 Amplification primers
[0114]
[0115]
[0116] (2) Induced expression and purification of recombinant proteins
[0117] The correctly sequenced recombinant expression plasmids pET-28a-YF-aPCV2 cap and pET-28a-YF-aPCV2 Rep were transformed into Escherichia coli BL21 (DE3) again, and a single colony was picked and inoculated into 10 mL LB / Ampr culture medium, and cultured at 37°C with shaking overnight. The next day, the bacterial liquid was inoculated into LB / Ampr culture medium at a ratio of 1:100, and cultured at 37°C with shaking for 2-4 h until the OD 600 When the value reaches 0.5-0.6, IPTG is added to a final concentration of 0.5 mmol / L, and the culture is continued at 37°C with shaking for 12 hours to induce expression. The induced expression sample is purified according to the instructions of the His.tag protein purification kit, and the target protein eluate is eluted step by step and collected to obtain purified recombinant YF-aPCV2 cap and YF-aPCV2 Rep proteins. The purified recombinant YF-aPCV2 cap and YF-aPCV2 Rep proteins are detected by SDS-PAGE (sodium dodecyl sulfate-polyacrylamide gel electrophoresis). The results are as follows: Fig.14 , Fig.15 shown.
[0118] The preparation method of the recombinant proteins QY-aPCV2 cap and QY-aPCV2 Rep is the same as the preparation method of the recombinant proteins YF-aPCV2 cap and YF-aPCV2 Rep.
[0119] (3) Identification of recombinant proteins
[0120] The purified recombinant YF-aPCV2 cap and YF-aPCV2 Rep proteins were subjected to SDS-PAGE electrophoresis and membrane transfer, and then blocked with 5% (m / v) skim milk powder at 4°C overnight. Mouse PCV2 Cap and PCV2 Rep primary antibodies were incubated, and HRP-labeled goat anti-mouse IgG was used as the secondary antibody for Western-blot identification. The results are shown in Fig.16 ,17 As shown, it was shown that the recombinant proteins YF-aPCV2 cap and YF-aPCV2 Rep were successfully obtained.
[0121] The identification of QY-aPCV2 cap and QY-aPCV2 Rep proteins was consistent with that of YF-aPCV2 cap and YF-aPCV2 Rep proteins.
[0122] Example 4
[0123] Preparation of ELISA plate for PCV2
[0124] The purified YF-aPCV2 Rep protein obtained in Example 3 was used as an antigen for coating. The YF-aPCV2 Rep protein was diluted to 2.0 μg / mL with ELISA coating buffer, and 100 μL of the diluted antigen was added to a 96-well ELISA plate and stored at 4°C overnight. After the antigen was coated, the coating solution (ELISA coating buffer) was discarded, and the plate was washed three times with 350 μL PBST (PBS containing 0.05% Tween-20), and then blocked with bovine serum albumin (BSA) (PBS containing 1% BSA) at 4°C for 12 hours. After blocking, the plate was washed three times with 350 μL PBST and dried at 37°C for 60 minutes.
[0125] Example 5
[0126] Establishment of indirect ELISA method for detection of aPCV2 Rep
[0127] (1) Determination of coating antigen concentration and antibody dilution concentration
[0128] The purified prokaryotic expressed YF-aPCV2 Rep protein in Example 3 was used as an antigen for coating. The antigen was diluted to 2.0, 1.0, 0.5, 0.25, and 0.1 μg / mL using a multiple dilution method, 100 μL per well, and coated overnight at 4°C. After the antigen was coated, the coating solution was discarded and a blocking solution was added for overnight blocking. The positive serum and negative serum were diluted 1:25, 1:50, and 1:100, respectively. The coating concentration and dilution multiple combination were set using the orthogonal method. Three replicates were set for each negative and positive sample, and the subsequent steps were carried out according to conventional procedures. The antigen coating concentration with a serum OD positive value of about 1.0 and the maximum positive OD / negative OD (P / N) ratio was the optimal working concentration. The orthogonal test results show (see Table 5) that when the coating antigen concentration is 2.0 μg / mL and the serum dilution ratio is 1:50, the OD450nm value of aPCV2 positive serum is close to 1.0, and the P / N ratio is the largest, which meets the selection conditions. Therefore, the optimal coating antigen concentration is 2.0 μg / ml, and the optimal serum dilution ratio is 1:50.
[0129] Table 5 Results of orthogonal test of concentration of coated YF-aPCV2 Rep antigen and antibody dilution concentration
[0130]
[0131]
[0132] Note: P / N* = positive serum OD450nm value / negative serum OD450nm value.
[0133] (2) Optimization of the working concentration of enzyme-labeled secondary antibodies
[0134] The enzyme-labeled secondary antibody optimization experiment was performed with an antigen coating concentration of 2.0 μg / mL and a serum dilution ratio of 1:50. The goat anti-chicken enzyme-labeled secondary antibody was diluted to three ratios, with concentrations of 1:10000, 1:20000, and 1:30000 for indirect ELISA. The reaction of each step was carried out at 37°C for 30 minutes and ended after 12 to 15 minutes of color development. The sample OD value was measured at a wavelength of 450nm. The enzyme secondary antibody concentration at which the P / N value was the largest was the optimal working concentration. The results are shown in Table 6. When the enzyme-labeled secondary antibody dilution ratio was 1:20000, the P / N value was the largest, so the optimal working concentration of the secondary antibody was 1:20000.
[0135] Table 6 Enzyme-labeled secondary antibody dilution results
[0136]
[0137] (3) Determination of the positive and negative critical value of indirect ELISA
[0138] 30 SPF poultry sera were selected as negative controls. The PCV2 antibody levels were detected according to the optimized ELISA steps. The OD450 values of each sample were read and the average OD450 values and their standard deviations of the 30 SPF poultry sera were calculated. According to the formula: OD450 average value + 3 times the standard deviation (SD). P / N is the OD450 value of positive serum / OD450 value of negative serum. The identification limit of P / N serum samples is 3 SDs of the negative control. The average absorbance of 30 negative serum samples at a wavelength of 450nm was 0.133, and the standard deviation of the absorbance was determined to be 0.039. Therefore, the critical value of ELISA is 0.133+3×0.039=0.250, and serum samples with OD450 nm equal to or higher than this critical value are positive.
[0139] (4) Performing ELISA detection based on the optimal screening results of (1) to (3) above, comprising the following steps:
[0140] 100 μL of serum diluted with sample diluent (1×PBS) was added to each well of the 96-well ELISA plate (obtained in Example 4), negative and positive controls were set, and incubated at 37°C for 60 min. After washing with PBST 5 times, each time for 2 to 3 min, 120 μL of horseradish peroxidase-labeled (HRP) goat anti-pig IgG secondary antibody, horseradish peroxidase-labeled (HRP) goat anti-chicken IgG secondary antibody, and horseradish peroxidase-labeled (HRP) goat anti-duck IgG secondary antibody diluted with PBST were added respectively. Incubate at 37°C for 30 min, then wash 5 times with 350 μL PBST, each time for 2 to 3 min. Finally, 100 μL of tetramethylbenzidine-hydrogen peroxide (TMB) solution was used as a substrate to observe the peroxidase reaction. After incubation at room temperature in the dark for 15 min, 50 μL of 2 M sulfuric acid was added to each well to stop the reaction, and the optical density (OD450) at 450 nm was read using a 450 nm microplate reader. Serum samples with OD450 nm equal to or higher than 0.250 were positive, otherwise they were negative.
[0141] Example 6
[0142] Specificity and repeatability of the detection method described in Example 5
[0143] Clinical sera specific for each of the following viruses were used: porcine circovirus type 3 (PCV3), porcine circovirus type 2 (aPCV2), porcine circovirus type 2 (PCV2), pseudorabies virus (PRV), porcine epidemic diarrhea virus (PEDV), porcine reproductive and respiratory syndrome virus (PRRSV), and classical swine fever virus (CSFV). These sera have been identified using commercial kits, and three sera of each pathogen were tested. According to the ELISA detection steps of step (4) of Example 5, negative controls and blank controls were set at the same time, and their OD450 values were statistically determined to determine the positive and negative to detect their specificity. The results are shown in Table 7. The OD450nm values of the positive sera of porcine circovirus type 2, pseudorabies virus, porcine reproductive and respiratory syndrome virus, porcine epidemic diarrhea virus, and classical swine fever virus are all less than the critical value of 0.250. Therefore, the indirect ELISA method established under this condition has a high specificity.
[0144] Table 7 Specificity test results
[0145]
[0146]
[0147] In order to evaluate the repeatability of the test, four negative and positive sera with different avian antibody levels were taken, and the ELISA detection step of step (4) of Example 5 was repeated three times within and between batches. The results are shown in Table 8. The coefficients of variation of the experimental results within and between batches were less than 10%, which shows that the detection method of the present invention has high repeatability.
[0148] Table 8 Repeatability test results
[0149]
[0150]
[0151] Example 7
[0152] Preparation of ELISA plate for aPCV2 cap
[0153] The purified YF-aPCV2 cap protein obtained in Example 3 was used as an antigen for coating. The YF-aPCV2 cap protein was diluted to 2.0 μg / mL with ELISA coating buffer, and 100 μL of the diluted antigen was added to a 96-well ELISA plate and stored at 4°C overnight. After the antigen was coated, the coating solution (ELISA coating buffer) was discarded, and the plate was washed three times with 350 μL PBST (PBS containing 0.05% Tween-20), and then blocked with bovine serum albumin (BSA) (PBS containing 1% BSA) at 4°C for 12 hours. After blocking, the plate was washed three times with 350 μL PBST and dried at 37°C for 60 minutes.
[0154] Example 8
[0155] Preparation and immune protection effect of subunit vaccines
[0156] 8.1 Vaccine preparation
[0157] (1) Calculate the amount and volume of antigen required for each injection. For subcutaneous or intramuscular injection, 50-200 μg of antigen is injected into each chick each time, and the injection volume is less than 50 μL; for intraperitoneal injection, the injection volume is 200-400 μL per chick each time. Strong detergents will weaken the emulsification effect and should be avoided. Prepare approximately 50% more vaccine than the final required amount.
[0158] (2) Select a syringe based on the total volume of the added materials. The total volume of the adjuvant and the QY-aPCV2 cap or QY-aPCV2 Rep or YF-aPCV2 cap or YF-aPCV2 Rep protein (antigen) obtained in Example 3 should be approximately half the volume of the syringe. For example, when preparing 2.5 ml of vaccine, use a 5 ml syringe for emulsification.
[0159] (3) Preheat Freund's complete adjuvant (or Freund's incomplete adjuvant) at 37°C before use, shake for 1-2 minutes or invert the bottle several times by hand to evenly resuspend the adjuvant. Pipette the required volume of Freund's complete adjuvant or Freund's incomplete adjuvant into the syringe, connect the syringe to the double-hole connector, and expel the air (excess air will hinder the formation of a stable emulsion).
[0160] (4) Aspirate the water-soluble antigen into another syringe and expel the air (excess air may hinder the formation of a stable emulsifier).
[0161] (5) Connect the syringe with antigen to one end of the two-hole connector. Make sure both syringes are securely fixed to the two-hole emulsification connector via Luer-lock.
[0162] (6) Push the piston steadily to allow all the antigen solution to pass through the two-hole connector and mix with Freund's complete adjuvant or Freund's incomplete adjuvant. Alternate between them and continue to transfer the mixture from one syringe to the other.
[0163] (7) Continue emulsification as above until a stable emulsion is formed. This will take several minutes. Push a small drop of emulsifier into a beaker of water. The small drop should form a stable oil droplet on the water surface. If the emulsion drops disperse on the water surface, reassemble the syringe and continue emulsification.
[0164] (8) Push all the emulsifier into a syringe. Remove the two-hole connector and add the injection needle. Alternatively, you can remove the empty syringe and replace it with a 1ml sterile syringe. At this time, the emulsifier can be transferred into the 1ml syringe for injection.
[0165] 8.2 Immune protection test
[0166] Fifty 15-day-old SPF chickens were purchased and then randomly divided into five groups (control group, QY-aPCV2 cap group, QY-aPCV2Rep group, YF-aPCV2 cap group, and YF-aPCV2 Rep group). They were rested for one week, and blood was collected on day 0. The first immunization was recorded as the first day. The second immunization was performed 14 days later, with a total of 300 μl of emulsified vaccine injected intramuscularly and subcutaneously each time. Blood was collected every 7 days during this period. PCV2 was challenged on day 35, with 400 μl PBS for each chicken in the control group and 400 μl virus liquid for each chicken in the experimental group. Then, the serum collected on days 0, 7, 14, 21, 28, and 35 was used to detect antibody levels. The experimental animals were killed on day 49 and samples were collected for detection. The antibodies in the Cap group were detected using the PCV2-dCap ELISA kit produced by Jinnuo Diagnostics, and the antibodies in the Rep group were detected using the ELISA detection method prepared by this patent. The antibody level results are shown in Table 1. Fig.18 and Fig.19 As shown, immune protection Fig. 20 and Fig.21 As shown, it is indicated that the subunit vaccine of the present invention has a protective effect on poultry.
[0167] Example 9
[0168] MDCC-MSB1 can be used to isolate and culture aPCV2
[0169] 9.1a Effect of PCV2 infection on MDCC-MSB1 cells
[0170] After MDCC-MSB1 cells were revived, they were cultured in RPMI 1640 medium containing 10% fetal bovine serum in a culture flask until the cells grew to 2×10 6 After that, centrifuge at 800r / min for 5min, discard the supernatant, add a small amount of fresh culture medium, and gently resuspend the cells.
[0171] The aPCV2 virus solution (isolated from 1.2 in Example 1) was diluted with a sterile 1640 at a volume ratio of 10%, then added to the resuspended cell solution, incubated for 1 hour, centrifuged at 800 r / min for 5 minutes, the supernatant was discarded, 10 ml of fresh culture medium was added, and then 300 mM D-glucosamine was added, and culture was continued for 24 and 48 hours, centrifuged at 800 r / min for 5 minutes, the supernatant was discarded, and WB lysis solution or 4% paraformaldehyde was added; the control group was PK-15, and the virus was inoculated when the PK-15 cells grew to a confluence of about 70%, and the medium was replaced with 2% DMEM. After culturing in a 37°C incubator for 24 hours and 48 hours, WB lysis solution or 4% paraformaldehyde was added. Then WB and IFA verification were performed.
[0172] 9.2WB Verification
[0173] (1) Sample preparation: discard the culture medium of the cells, add WB cell lysis buffer and 1% protease phosphatase inhibitor (operation is performed on ice), repeatedly blow with a pipette to make the cells fall off the wall, and transfer to a 1.5mL centrifuge tube. (2) Electrophoresis: protein loading, first run electrophoresis at 85V constant voltage until the protein band runs from the concentrated gel to the separation gel, adjust the voltage to 100V, and stop when the protein band runs to the appropriate position. (3) Transfer: PVDF membrane is placed in formaldehyde solution (cooled to -20℃ in advance) for activation, and the membrane is transferred using the wet transfer method (the transfer solution needs to be cooled to -20℃ in advance). The transfer is performed in an ice bath and the membrane is transferred at 100V for 2h. (4) Blocking: After the transfer is completed, take out the membrane, put it face up in a box containing skimmed milk powder blocking solution, and block it at room temperature for 2h. (5) Wash the membrane: wash the membrane five times with PBST elution solution on a shaker, each wash for 5min. (6) Incubate with primary antibody: incubate overnight at 4℃. The primary antibody was diluted with primary antibody diluent at a ratio of 1:1000. (7) Washing the membrane: Same as step (5). (8) Incubating the secondary antibody: Place the membrane in the diluted secondary antibody solution and incubate on a shaker at room temperature for 1 hour. The secondary antibody used was goat anti-mouse secondary antibody, which was diluted with secondary antibody diluent at a ratio of 1:5000. (9) Washing the membrane: Same as step (5). (10) Exposure: Mix the A and B solutions in the ultrasensitive ECL chemiluminescence kit in a ratio of 1:1, place the membrane in the mixture, expose the membrane using the instrument, take a picture and save the result. The result is as follows. Fig. 22 As shown (three parallel experiments were performed).
[0174] 9.3 IFA Identification
[0175] The cells were fixed with 4% paraformaldehyde and then tested by IFA. The fluorescence was observed under a fluorescence microscope and the required results were photographed and stored. Fig.23 shown.
[0176] Depend on Fig. 22 and Fig.23 It can be seen that MDCC-MSB1 can be infected with avian aPCV2 virus, and the infection efficiency is higher than PK-15. Therefore, MDCC-MSB1 can be used to isolate and culture avian porcine circovirus type 2.
[0177] Example 10
[0178] PCV2 isolation test in chicken embryos
[0179] 40 SPF-grade fertilized eggs were purchased and incubated in a 37°C incubator. At the 8th day of age, they were randomly divided into two groups (experimental group and control group). The experimental group injected 200 μl of virus liquid into the allantoic cavity using PK-15 to separate porcine PCV2 virus liquid (the PK-15 method for separating porcine circovirus type 2 was carried out in the article by Xu Pengli et al. (Xu Pengli, 2018)) in a sterile clean bench. The control group was not treated. Then they were returned to the 37°C incubator for incubation for 72 hours, and then the allantoic fluid was collected under sterile conditions to obtain the virus, and the total viral nucleic acid was extracted and tested by q-PCR. The method of separating porcine circovirus type 2 by PK-15 in the article by Xu Pengli et al. was used as the control group. The results are as follows Fig.24 As shown, it was found that the virus content isolated from chicken embryos was higher than that isolated from traditional PK-15 cells.
[0180] This example shows that porcine PCV2 can infect poultry. At the same time, a higher titer of porcine circovirus from porcine can be detected in the allantoic fluid, indicating that this method can be used to isolate porcine circovirus type 2.
[0181] The above is only a preferred embodiment of the present invention. It should be pointed out that for ordinary technicians in this technical field, several improvements and modifications can be made without departing from the principle of the present invention. These improvements and modifications should also be regarded as the scope of protection of the present invention.
Claims
1. an aPCV2 gene, It is characterized in that The nucleotide sequence of the aPCV2 gene includes any one of the following: (1) SEQ ID NO.1, (2) SEQ ID NO.2, (3) a sequence having a homology of more than 90% with SEQ ID NO.1, (4) a sequence having a homology of more than 90% with SEQ ID NO.
2.
2. Use of the aPCV2 gene according to claim 1 in the preparation of PCV2 vaccine.
3. An expression vector, It is characterized in that The expression vector contains the Cap gene or Rep gene in the aPCV2 gene of claim 1, the nucleotide sequence of the Cap gene includes SEQ ID NO.3 or SEQ ID NO.4, and the nucleotide sequence of the Rep gene includes SEQ ID NO.5 or SEQ ID NO.
6.
4. A host cell, It is characterized in that The host cell contains the expression vector according to claim 3.
5. A recombinant protein, It is characterized in that The recombinant protein is obtained by inducing the host cell according to claim 4 to express and purify it.
6. Use of the expression vector according to claim 3, the host cell according to claim 4 or the recombinant protein according to claim 5 in preparing a product for detecting PCV2 or in preparing a PCV2 vaccine.
7. An ELISA test plate for detecting PCV2, It is characterized in that The ELISA test plate is coated with the recombinant protein according to claim 5, and the coating concentration of the recombinant protein is 1.0 μg / ml-2.0 μg / ml.
8. An inactivated vaccine, It is characterized in that It includes a virus strain containing the aPCV2 gene of claim 1.
9. A subunit vaccine, It is characterized in that The invention comprises the recombinant protein according to claim 5 and an adjuvant.
10. A method for efficiently isolating PCV2, It is characterized in that The method comprises the following steps: injecting PCV2 virus liquid into the allantoic cavity of 8-11 day old avian embryos, collecting the allantoic fluid after incubation to obtain PCV2 virus, wherein the PCV2 virus liquid comprises avian PCV2 virus liquid or swine PCV2 virus liquid, and the avian PCV2 virus liquid is a virus liquid of a virus strain containing the aPCV2 gene according to claim 1.
11. Use of the MDCC-MSB1 cell line in isolating and culturing porcine PCV2 or avian PCV2, wherein the avian PCV2 is a virus strain containing the aPCV2 gene of claim 1.
Citation Information
Patent Citations
Gene for encoding Cap protein of porcine circovirus 2 and application thereof
CN107337718A
Poultry source PCV3 gene and application thereof
CN118497227A
Porcine circovirus type 2, immune composition containing the same, assay kit, and use thereof
WO2012083837A1
